NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE180748 Query DataSets for GSE180748
Status Public on Jul 25, 2021
Title CHIP-Seq analysis of CREB1 binding after ALVAC vaccination in NHP
Organism Macaca mulatta
Experiment type Genome binding/occupancy profiling by high throughput sequencing
Summary The RV144 HIV vaccine trial remains the only study to demonstrate significant protection from future HIV-1 acquisition. One of the key components of the RV144 vaccine was the use of the canarypox vector ALVAC as the priming component. Since AIDSVAX, the booster component, alone failed to provide protection we hypothesized that the ALVAC prime contributed significantly to the generation of protection. To test this, we designed a NHP immunogenicity trial to mechanistically link ALVAC vaccination with the magnitude of V1V2 titers, the most significant immune correlate of reduced HIV-1 acquisition in RV144. Our objective was to use a systems biology approach to identify the transcription factors, target genes and immune pathways which were being induced by ALVAC vaccination and associated with higher V1V2 titers. We identified the transcription factor CREB1 and its target genes as rapidly induced by ALVAC in multiple immune subsets and that CREB1 drives the expression and activation of a network of other TFs which are critical for modulating immune responses. Pathways induced by this ALVAC-CREB1 axis include lymphocyte/leukocyte migration, lymphocyte differentiation, antigen processing and presentation, T cell co-stimulation and cytokine signaling.
 
Overall design PBMCs were infected in vitro with an MOI 10:1 of ALVAC-HIV or empty ALVAC, with media cultured cells as a control. ALVAC-infected PBMCs were compared with media condition at 24 and 48 hours after CREB1 chromatin immunoprecipitation.
 
Contributor(s) Tomalka JA, Pelletier A, Fourati S, Latif MB, Sharma A, Furr K, Carlson K, Lifton M, Gonzalez A, Wilkinson P, Franchini G, Parks R, Letvin N, Nicole LY, Kelly ES, Tomaras G, Tartaglia J, Robb M, Michael N, Koup R, Haynes B, Santra S, Sékaly R
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Jul 23, 2021
Last update date Jul 25, 2021
Contact name Adam-Nicolas Pelletier
E-mail(s) adam.nicolas.pelletier@rpmbioinfo-solutions.com
Phone 438-530-2957
Organization name RPM Bioinfo Solutions
Street address 97, Montcalm
City Blainville
State/province Quebec
ZIP/Postal code J7C 2R7
Country Canada
 
Platforms (1)
GPL27943 Illumina NovaSeq 6000 (Macaca mulatta)
Samples (15)
GSM5469941 Monkey1_media_24hr
GSM5469942 Monkey1_vCp1521_24hr
GSM5469943 Monkey2_media_24hr
This SubSeries is part of SuperSeries:
GSE180749 CHIP-Seq analysis of CREB1 binding after ALVAC vaccination
Relations
BioProject PRJNA749327
SRA SRP329652

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE180748_NHP_24hr_ALVAC_empty_vs_media_optimal.narrowPeak.gz 8.5 Mb (ftp)(http) NARROWPEAK
GSE180748_NHP_24hr_ALVAC_full_vs_media_optimal.narrowPeak.gz 5.2 Mb (ftp)(http) NARROWPEAK
GSE180748_NHP_48hr_ALVAC_empty_vs_media_optimal.narrowPeak.gz 7.8 Mb (ftp)(http) NARROWPEAK
GSE180748_NHP_48hr_ALVAC_full_vs_media_optimal.narrowPeak.gz 3.9 Mb (ftp)(http) NARROWPEAK
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap